𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Antitumor activity of imatinib mesylate in neuroblastoma xenografts

✍ Scribed by Daniela Meco; Anna Riccardi; Tiziana Servidei; Josef Brueggen; Marco Gessi; Riccardo Riccardi; Carlo Dominici

Book ID
116333684
Publisher
Elsevier Science
Year
2005
Tongue
English
Weight
264 KB
Volume
228
Category
Article
ISSN
0304-3835

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Imatinib mesylate potentiates topotecan
Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models
✍ Heather P. McDowell; Daniela Meco; Anna Riccardi; Barbara Tanno; Anna C. Berardi πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 French βš– 331 KB

## Abstract High levels of PDGFR expression in primary rhabdomyosarcoma (RMS) have been associated with disease progression. To date however, there are no reports on the activity of imatinib mesylate, a selective PDGFR inhibitor, in RMS preclinical models. A panel of 5 RMS cell lines was used to in

The selective VEGFR1-3 inhibitor axitini
The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
✍ Jochen RΓΆssler; Yann Monnet; Francoise Farace; Paule Opolon; Estelle Daudigeos-D πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 French βš– 533 KB

## Abstract Tumor angiogenesis in childhood neuroblastoma is an important prognostic factor suggesting a potential role for antiangiogenic agents in the treatment of high‐risk disease. Within the KidsCancerKinome project, we evaluated the new oral selective pan‐VEGFR tyrosine kinase inhibitor axiti